Last reviewed · How we verify

Cytarabine or Supportive Care

Eisai Inc. · Phase 3 active Small molecule

Cytarabine or Supportive Care is a Nucleoside analog; antimetabolite Small molecule drug developed by Eisai Inc.. It is currently in Phase 3 development for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.

Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells.

Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.

At a glance

Generic nameCytarabine or Supportive Care
SponsorEisai Inc.
Drug classNucleoside analog; antimetabolite
TargetDNA polymerase; incorporated into DNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Cytarabine (ara-C) is a nucleoside analog that mimics cytidine and becomes phosphorylated intracellularly to its active triphosphate form. This active metabolite is incorporated into DNA during synthesis, causing chain termination and inhibition of DNA polymerase. It is primarily effective against rapidly dividing cells, particularly hematopoietic malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cytarabine or Supportive Care

What is Cytarabine or Supportive Care?

Cytarabine or Supportive Care is a Nucleoside analog; antimetabolite drug developed by Eisai Inc., indicated for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.

How does Cytarabine or Supportive Care work?

Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells.

What is Cytarabine or Supportive Care used for?

Cytarabine or Supportive Care is indicated for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase, Lymphoma.

Who makes Cytarabine or Supportive Care?

Cytarabine or Supportive Care is developed by Eisai Inc. (see full Eisai Inc. pipeline at /company/eisai).

What drug class is Cytarabine or Supportive Care in?

Cytarabine or Supportive Care belongs to the Nucleoside analog; antimetabolite class. See all Nucleoside analog; antimetabolite drugs at /class/nucleoside-analog-antimetabolite.

What development phase is Cytarabine or Supportive Care in?

Cytarabine or Supportive Care is in Phase 3.

What are the side effects of Cytarabine or Supportive Care?

Common side effects of Cytarabine or Supportive Care include Myelosuppression (neutropenia, thrombocytopenia, anemia), Nausea and vomiting, Mucositis, Diarrhea, Hepatotoxicity, Neurotoxicity (at high doses).

What does Cytarabine or Supportive Care target?

Cytarabine or Supportive Care targets DNA polymerase; incorporated into DNA and is a Nucleoside analog; antimetabolite.

Related